RT Journal Article
SR Electronic
T1 Evaluating strategies for spatial allocation of vaccines based on risk and centrality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.07.21263209
DO 10.1101/2021.09.07.21263209
A1 Singer, Benjamin J
A1 Thompson, Robin N
A1 Bonsall, Michael B
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.07.21263209.abstract
AB When vaccinating a large population in response to an invading pathogen, it is often necessary to prioritise some individuals to be vaccinated first. One way to do this is to choose individuals to vaccinate based on their location. Methods for this prioritisation include strategies which target those regions most at risk of importing the pathogen, and strategies which target regions with high centrality on the travel network. We use a simple infectious disease epidemic model to compare a risk-targeting strategy to two different centrality-targeting strategies based on betweenness centrality and random walk percolation centrality, respectively. We find that the relative effectiveness of these strategies in reducing the total number of infections varies with the basic reproduction number of the pathogen, travel rates, structure of the travel network, and vaccine availability. We conclude that, when a pathogen has high spreading capacity, or when vaccine availability is limited, centrality-targeting strategies should be considered as an alternative to the more commonly used risk-targeting strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the Biotechnology and Biological Sciences Research Council (BBSRC) [grant number BB/M011224/1].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Oxford Central University Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are freely available from the sources cited in the text. The Python code written for this study is available at \url{https://osf.io/gs9cp/}.